Earth Science TechETST -20.26%37 Return-on-Tangible-Equity is 150.58% as of Mar. 2026, which is 16% above its 10-year median of 129.72. GuruFocus rates ETST with a GF Score™ of 37/100 and a GF Value™ of $0.24 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 898 Drug Manufacturers companies, Earth Science Tech ranks better than 93.32% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Earth Science Tech's annualized net income for the quarter that ended in Mar. 2026 was $5.16 Mil. Earth Science Tech's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $3.42 Mil. Therefore, Earth Science Tech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 150.58%.
The historical rank and industry rank for Earth Science Tech's Return-on-Tangible-Equity or its related term are showing as below:
ETST'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -407.1 Med: 129.72 Max: 475.38
Current: 155.52
During the past 13 years, Earth Science Tech's highest Return-on-Tangible-Equity was 475.38%. The lowest was -407.10%. And the median was 129.72%.
ETST's Return-on-Tangible-Equity is ranked better than 93.32% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs ETST: 155.52
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Earth Science Tech Return-on-Tangible-Equity Related Terms
Earth Science Tech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Earth Science Tech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ETST vs IXHL, BTAI, TLPH: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Earth Science Tech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Earth Science Tech Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Earth Science Tech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Earth Science Tech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 150.58% mean?
Earth Science Tech (ETST) has a Return-on-Tangible-Equity of 150.58% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Earth Science Tech and its competitors. This is 16% above median its historical median of 129.72. According to the industry distribution chart, Earth Science Tech ranks #60 out of 898 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is Earth Science Tech's Return-on-Tangible-Equity too high?
Earth Science Tech's current Return-on-Tangible-Equity of 150.58% is 16% above median its 10-year median of 129.72. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Earth Science Tech's value of 150.58% is 1810.9% above this industry median. Based on the distribution chart, Earth Science Tech ranks #60 out of 898 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Earth Science Tech has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Earth Science Tech's Return-on-Tangible-Equity compare to IXHL and BTAI?
According to the Drug Manufacturers industry distribution chart, Earth Science Tech ranks #60 out of 898 companies for Return-on-Tangible-Equity. This places Earth Science Tech in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.88. Earth Science Tech's value of 150.58% is 1810.9% above this benchmark. While the company's 10-year median is 129.72 vs. the industry median of 7.88, Earth Science Tech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Earth Science Tech's current Return-on-Tangible-Equity of 150.58% is 1810.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Earth Science Tech and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Earth Science Tech's current Return-on-Tangible-Equity is 150.58%, which is 16% above median its own 10-year median of 129.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Earth Science Tech stock overvalued right now?
Based on GuruFocus' analysis, Earth Science Tech (ETST) is currently considered Possible Value Trap. The stock's GF Value™ is $0.24, compared to a current price of $0.14 — trading 43.8% below its estimated fair value. The current Return-on-Tangible-Equity is 150.58%, which is 16% above median its 10-year median of 129.72 and 1810.9% above the Drug Manufacturers industry median of 7.88. Earth Science Tech's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Earth Science Tech (ETST), the current Return-on-Tangible-Equity is 150.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Earth Science Tech (ETST) Overvalued in 2026?
Based on GuruFocus' analysis, Earth Science Tech stock appears to be undervalued.
The current stock price of $0.14 is trading 43.8% below its estimated GF Value™ of $0.24.
GuruFocus considers Earth Science Tech to be Possible Value Trap.
Key valuation signals for ETST:
Return-on-Tangible-Equity: 150.58% (16% above median its 10-year median of 129.72)
GF Value™: $0.24 vs. price of $0.14 (43.8% below fair value)
Industry Position: 1810.9% above the Drug Manufacturers median (#60 of 898)
No single metric tells the full story. See the ETST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Earth Science Tech Inc is a diversified holding company. The company focuses on the health and wellness sector. The Company's principal operating plan is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business. The core of the Company's value proposition is the seamless integration of patient care, from consultation to fulfillment.
37GF Score
Get the complete analysis for ETST
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETST has been successfully added to your 
